Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

ClinicalTrials.gov ID: NCT00326144

Public ClinicalTrials.gov record NCT00326144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder

Study identification

NCT ID
NCT00326144
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
310 participants

Conditions and interventions

Interventions

  • Quetiapine fumarate Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Not listed
Completion
Apr 30, 2007
Last update posted
Mar 24, 2009

2006 – 2007

United States locations

U.S. sites
34
U.S. states
20
U.S. cities
34
Facility City State ZIP Site status
Research Site Phoenix Arizona
Research Site Little Rock Arkansas
Research Site Anaheim California
Research Site El Centro California
Research Site Garden Grove California
Research Site National City California
Research Site Riverside California
Research Site Hartford Connecticut
Research Site Wilmington Delaware
Research Site Altamonte Springs Florida
Research Site DeLand Florida
Research Site Maitland Florida
Research Site New Port Richey Florida
Research Site Atlanta Georgia
Research Site Decatur Georgia
Research Site Roswell Georgia
Research Site Naperville Illinois
Research Site Indianapolis Indiana
Research Site Lafayette Indiana
Research Site Owensboro Kentucky
Research Site New Orleans Louisiana
Research Site Braintree Massachusetts
Research Site Cambridge Massachusetts
Research Site Pittsfield Massachusetts
Research Site Minneapolis Minnesota
Research Site St Louis Missouri
Research SIte Staten Island New York
Research Site Avon Lake Ohio
Research Site Cincinnati Ohio
Research Site Oklahoma City Oklahoma
Research Site Allentown Pennsylvania
Research Site Memphis Tennessee
Research Site DeSoto Texas
Research Site Houston Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00326144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2009 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00326144 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →